<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01310712</url>
  </required_header>
  <id_info>
    <org_study_id>University of Sao Paulo</org_study_id>
    <nct_id>NCT01310712</nct_id>
  </id_info>
  <brief_title>Use of Oxybutynin for Treating Hyperhidrosis: A Placebo-control Study</brief_title>
  <official_title>Use of Oxybutynin for Treating Hyperhidrosis: A Placebo-control Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Video-assisted thoracic sympathectomy (VATS) provides excellent resolution of palmar and
      axillary hyperhidrosis but is associated with compensatory hyperhidrosis. Low doses of
      Oxybutynin can be used to treat palmar hyperhidrosis with fewer side effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Introduction: Video-assisted thoracic sympathectomy (VATS) provides excellent resolution of
      palmar and axillary hyperhidrosis but is associated with compensatory hyperhidrosis. Low
      doses of Oxybutynin can be used to treat palmar hyperhidrosis with fewer side effects.

      Purpose: The objective of this study is to evaluate the effectiveness and patient
      satisfaction with the use of oxybutynin at low doses comparing to placebo for treating palmar
      hyperhidrosis.

      Methods: This is a prospective, randomized and controlled study. From December 2010 to
      february 2011, 50 consecutive patients with palmar hyperhidrosis were treated with oxybutynin
      or placebo. Data were collected from 50 patients, and 5 (10,0%) patients were lost to
      follow-up. During the first week, patients received 2.5 mg of oxybutynin once a day in the
      evening. From the 8th to the 42nd day, they received 2.5 mg twice a day, and from the 43rd
      day to the end of the 12th week, they received 5 mg twice a day. All of the patients
      underwent 2 evaluations: before and after (12 weeks) the oxybutynin treatment, using a
      clinical questionnaire; and a clinical protocol for quality of life (QOL).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of Quality of life in patients with hyperhidrosis with the use of oxybutynin</measure>
    <time_frame>6 weeks</time_frame>
    <description>Using a Quality of life protocol we will study if patients with hyperhidrosis using oxybutynin have an improvement in their quality of life</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The use of oxybutynin diminishes hyperhidrosis</measure>
    <time_frame>6 weeks</time_frame>
    <description>if the use of oxybutynin diminishes hyperhidrosis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Hyperhidrosis</condition>
  <arm_group>
    <arm_group_label>oxybutynin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients will receive in the end of the treatment, 10 mg of oxybutynin a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxybutynin</intervention_name>
    <description>5 mg every 12 hours for 6 weeks</description>
    <arm_group_label>oxybutynin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo twice a day for 42 days.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients with hyperhidrosis

        Exclusion Criteria:

          -  Glaucoma and pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>WOLOSKER NELSON, Md, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital das Clinicas da FMUSP</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05679040</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2011</study_first_submitted>
  <study_first_submitted_qc>March 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2011</study_first_posted>
  <last_update_submitted>September 21, 2011</last_update_submitted>
  <last_update_submitted_qc>September 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Nelson Wolosker</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>hyperhidrosis</keyword>
  <keyword>oxybutynin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperhidrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxybutynin</mesh_term>
    <mesh_term>Mandelic Acids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

